biostudies-literatureUnknown12(9)Bhan VNovartis Canada<b>Aim:</b> The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. <b>Materials & methods:</b> A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5 years following switch from commonly used first-line therapies. <b>Results:</b> Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes. <b>Conclusion:</b> Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.Journal of comparative effectiveness researche220175https://www.ebi.ac.uk/biostudies/studies/S-EPMC10690431biostudies-literatureCost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.PMC10690431Vudumula UPatel BPMouallif SAdlard NGrima DThomas KBhan VClift FBlanchette FGudala KDutta NFarhane FBaharnoori MfalseCost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada.<b>Aim:</b> The costs and consequences of initial and delayed ofatumumab treatment were evaluated in relapsing-remitting multiple sclerosis with active disease in Canada. <b>Materials & methods:</b> A Markov cohort model was used (10-year horizon, annual cycle length, 1.5% discounting). Scenario analyses examined ofatumumab as first-line treatment versus 3 and 5 years following switch from commonly used first-line therapies. <b>Results:</b> Ofatumumab resulted in improvements in clinical outcomes (relapses and disease progression) and productivity (employment and full-time work), and reduction of economic burden (administration, monitoring and non-drug costs) that were comparable to other high-efficacy therapies (ocrelizumab, cladribine and natalizumab). Switching to ofatumumab earlier in the disease course may improve these outcomes. <b>Conclusion:</b> Results highlight the value of a high-efficacy therapy such as ofatumumab as initial treatment (i.e., first-line) in newly diagnosed relapsing-remitting multiple sclerosis patients with active disease.2023-01-01T00:00:00Z2023 Sep2026-05-28T21:35:10.433Z2025-04-19T20:19:50.393ZS-EPMC106904313760689710.57264/cer-2022-0175